IBDEI0C8 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5808,1,4,0)
 ;;=4^MULTINODULAR
 ;;^UTILITY(U,$J,358.3,5808,1,5,0)
 ;;=5^241.1
 ;;^UTILITY(U,$J,358.3,5808,2)
 ;;=^267790
 ;;^UTILITY(U,$J,358.3,5809,0)
 ;;=242.20^^49^521^11
 ;;^UTILITY(U,$J,358.3,5809,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5809,1,4,0)
 ;;=4^MULTINODULAR,TOXIC
 ;;^UTILITY(U,$J,358.3,5809,1,5,0)
 ;;=5^242.20
 ;;^UTILITY(U,$J,358.3,5809,2)
 ;;=^267801
 ;;^UTILITY(U,$J,358.3,5810,0)
 ;;=242.00^^49^521^4
 ;;^UTILITY(U,$J,358.3,5810,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5810,1,4,0)
 ;;=4^GRAVES DISEASE
 ;;^UTILITY(U,$J,358.3,5810,1,5,0)
 ;;=5^242.00
 ;;^UTILITY(U,$J,358.3,5810,2)
 ;;=^267793
 ;;^UTILITY(U,$J,358.3,5811,0)
 ;;=244.9^^49^521^8
 ;;^UTILITY(U,$J,358.3,5811,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5811,1,4,0)
 ;;=4^HYPOTHYROIDISM NOS
 ;;^UTILITY(U,$J,358.3,5811,1,5,0)
 ;;=5^244.9
 ;;^UTILITY(U,$J,358.3,5811,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,5812,0)
 ;;=244.1^^49^521^12
 ;;^UTILITY(U,$J,358.3,5812,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5812,1,4,0)
 ;;=4^POST I-131
 ;;^UTILITY(U,$J,358.3,5812,1,5,0)
 ;;=5^244.1
 ;;^UTILITY(U,$J,358.3,5812,2)
 ;;=^267816
 ;;^UTILITY(U,$J,358.3,5813,0)
 ;;=244.0^^49^521^13
 ;;^UTILITY(U,$J,358.3,5813,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5813,1,4,0)
 ;;=4^POSTSURGICAL HYPOTHYROID
 ;;^UTILITY(U,$J,358.3,5813,1,5,0)
 ;;=5^244.0
 ;;^UTILITY(U,$J,358.3,5813,2)
 ;;=^267814
 ;;^UTILITY(U,$J,358.3,5814,0)
 ;;=246.0^^49^521^6
 ;;^UTILITY(U,$J,358.3,5814,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5814,1,4,0)
 ;;=4^HYPERTHYROCALCITONIN
 ;;^UTILITY(U,$J,358.3,5814,1,5,0)
 ;;=5^246.0
 ;;^UTILITY(U,$J,358.3,5814,2)
 ;;=^267827
 ;;^UTILITY(U,$J,358.3,5815,0)
 ;;=241.0^^49^521^16
 ;;^UTILITY(U,$J,358.3,5815,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5815,1,4,0)
 ;;=4^THYROID NODULE
 ;;^UTILITY(U,$J,358.3,5815,1,5,0)
 ;;=5^241.0
 ;;^UTILITY(U,$J,358.3,5815,2)
 ;;=^83865
 ;;^UTILITY(U,$J,358.3,5816,0)
 ;;=242.10^^49^521^17
 ;;^UTILITY(U,$J,358.3,5816,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5816,1,4,0)
 ;;=4^THYROID NODULE,HOT
 ;;^UTILITY(U,$J,358.3,5816,1,5,0)
 ;;=5^242.10
 ;;^UTILITY(U,$J,358.3,5816,2)
 ;;=^267797
 ;;^UTILITY(U,$J,358.3,5817,0)
 ;;=245.0^^49^521^1
 ;;^UTILITY(U,$J,358.3,5817,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5817,1,4,0)
 ;;=4^ACUTE THYROIDITIS
 ;;^UTILITY(U,$J,358.3,5817,1,5,0)
 ;;=5^245.0
 ;;^UTILITY(U,$J,358.3,5817,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,5818,0)
 ;;=245.2^^49^521^2
 ;;^UTILITY(U,$J,358.3,5818,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5818,1,4,0)
 ;;=4^CHR LYMPHOCYT THYROIDIT
 ;;^UTILITY(U,$J,358.3,5818,1,5,0)
 ;;=5^245.2
 ;;^UTILITY(U,$J,358.3,5818,2)
 ;;=^119344
 ;;^UTILITY(U,$J,358.3,5819,0)
 ;;=245.1^^49^521^14
 ;;^UTILITY(U,$J,358.3,5819,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5819,1,4,0)
 ;;=4^SUBACUTE THYROIDITIS
 ;;^UTILITY(U,$J,358.3,5819,1,5,0)
 ;;=5^245.1
 ;;^UTILITY(U,$J,358.3,5819,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,5820,0)
 ;;=252.1^^49^521^7
 ;;^UTILITY(U,$J,358.3,5820,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5820,1,4,0)
 ;;=4^HYPOPARATHYROIDISM
 ;;^UTILITY(U,$J,358.3,5820,1,5,0)
 ;;=5^252.1
 ;;^UTILITY(U,$J,358.3,5820,2)
 ;;=^60635
 ;;^UTILITY(U,$J,358.3,5821,0)
 ;;=252.01^^49^521^5
 ;;^UTILITY(U,$J,358.3,5821,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5821,1,4,0)
 ;;=4^HYPERPARATHYROID,PRIMARY
 ;;^UTILITY(U,$J,358.3,5821,1,5,0)
 ;;=5^252.01
 ;;^UTILITY(U,$J,358.3,5821,2)
 ;;=^331439
 ;;^UTILITY(U,$J,358.3,5822,0)
 ;;=252.02^^49^521^9
 ;;^UTILITY(U,$J,358.3,5822,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5822,1,4,0)
 ;;=4^HYPRPRTHYRD NONRENAL,SEC
